Importance: An infective etiology of acute peripheral vestibulopathy (APV) has long been hypothesized. In the context of coronavirus disease 2019 (COVID-19), we examined the possible comorbidity between these two entities.
Objectives: APV is the second most common cause of vestibular disorders and results from a sudden and unilateral loss of vestibular inputs. The characteristic signs and symptoms include sudden and prolonged vertigo, absence of auditory symptoms, and absence of other neurological symptoms. An infective etiology of APV has long been hypothesized on the basis of its association with respiratory tract infections and its frequent occurrence in epidemics. Possible comorbidity with herpes simplex virus type 1 reactivation or influenza virus infection has also been proposed. This study was designed to assess the possible comorbidity between APV and COVID-19.
Design/setting/participants: Quantification of the number of hospital admissions for APV over the period from February to May 2020 was carried out in 5 French hospitals. A comparison with 2018 and 2019 entries over the same period was made. Comorbidity between APV and COVID-19 infection was investigated.
Results: No significant increase in admission for APV was noticed over the examination period. No significant difference was noticed among hospitals located in COVID-19 high- and low-risk zones for SARS-CoV-2. No significant increase in the severity of the APV cases was noticed. No case of comorbidity between APV and SARS-CoV-2 infection was reported. Based on our observations, no correlation was made between APV and COVID-19.
Conclusion: Based on our observations, COVID-19 is not statistically correlated with APV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAO.0000000000003216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease.
Biomedicines
November 2024
Referral Center for Fabry Disease and Lysosomal Diseases, MetabERN, F-92380 Garches, France.
Article Synopsis
- Fabry disease presents complex challenges in patient care, and while enzyme replacement therapy (agalsidase beta) is beneficial, its long infusion time can be burdensome for patients.
- A study involved 39 adult patients with Fabry disease to evaluate the safety of reducing the infusion time to 90 minutes without premedication, with a total of 85 infusions conducted.
- The findings showed no reported adverse events, stable vital signs, and high patient satisfaction, indicating that shorter infusion times are safe and feasible for patients with Fabry disease.*
Clinical characteristics and outcomes of children, adolescents and young adults with overweight or obesity and mental health disorders.
Int J Obes (Lond)
March 2024
University of Ulm, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany.
Background: Mental disorders are important comorbidities in youth with obesity. Aim was to describe the clinical characteristics and outcome of youth with overweight or obesity having comorbid mental disorders.
Methods: Data from children, adolescents, and young adults (age 6-30 years) with overweight or obesity and mental disorders (depression, anxiety disorder, eating disorder, attention deficit disorder (ADHD)) from 226 centers in Germany and Austria participating in the Adiposity Patient Registry (APV) were analyzed and compared with those without reported mental disorders using regression modeling.
Limitations of BMI z scores for assessing weight change: A clinical tool versus individual risk.
Obesity (Silver Spring)
March 2024
Department of Pediatrics, Division of Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, California, USA.
Although pediatric growth curves provide clinical utility, using these metrics for within-person change over time can be misleading. As research is focused on understanding cardiometabolic consequences of weight gain, it is important to use precise metrics to analyze these longitudinal research questions. Despite several foundational recommendations to limit the use of reference pediatric growth curves (e.
View Article and Find Full Text PDFBMI Z-Score (SDS) versus Calculated Body Fat Percentage: Association with Cardiometabolic Risk Factors in Obese Children and Adolescents.
Ann Nutr Metab
February 2024
Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany.
Introduction: BMI or BMI-standardized deviation score (SDS) in children and adolescents is still the standard for weight classification. [BMJ. 2019;366:4293] developed a formula to calculate body fat percentage (%BF) based on age, sex, height, weight, and ethnicity.
View Article and Find Full Text PDFGlucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
touchREV Endocrinol
May 2023
Division of Endocrinology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the management of type 2 diabetes and obesity. Unlike several classes of antidiabetic medications that contribute to weight gain, GLP-1RAs not only reduce haemoglobin A1c, but also promote weight loss. While there is a large body of evidence supporting its safety and efficacy in adults, paediatric clinical trial data have only emerged in recent years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!